Since September 19, 2016, QPS has closely collaborated with G-CURE, a cardiovascular research organization originating from and closely linked to the Department of Cardiology at the University Medical Center Groningen (UMCG) in the Netherlands. Now, three years later, QPS and G-CURE are transforming their relationship into a partnership, establishing an internationally competitive cardiovascular drug development infrastructure. By combining expertise and experience with cardiovascular research, Phase I clinical pharmacology, and Phase II – IV cardiovascular clinical trials, the QPS and UMCG/G-CURE partnership will offer comprehensive cardiovascular drug development programs for pharmaceutical and biotech companies.
G-CURE and QPS have similar company cultures, and this partnership is expected to produce a better alignment of their capabilities; therefore, the clients of both parties will benefit from this optimized arrangement. To better define the partnership, G-CURE will handle preclinical/experimental/translational (animal) studies and the patient phases of projects, while QPS will lead the healthy volunteer phases of new projects in close collaboration with UMCG and G-CURE. QPS may also provide bioanalysis and clinical research support for Phase I-IV clinical trials using their local laboratories and offices.
In gaining a highly experienced new partner, QPS will be able to offer state-of-the-art cardiovascular expertise, including Phase I-IV cardiovascular clinical trials, in addition to its current range of services focused on the central nervous system, dermatology, and female health.
The cardiovascular specialists involved in this collaboration have a world-renowned understanding of cardiovascular physiology and pathophysiology, providing significant added value to clients. QPS and G-CURE will focus on several specific cardiovascular target areas:
- Genetic Cardiomyopathies
- Acute Coronary Syndromes
- Arrhythmias (in particular Atrial Fibrillation)
- Heart Failure
If you are interested in more information about QPS and G-CURE’s capabilities in any of the above-mentioned target areas, or if you are interested in working with them in this exciting new partnership, please reach out to one of the contacts below.
About QPS Holdings, LLC
QPS is a global contract research organization (CRO) providing discovery, preclinical, and clinical drug development services since 1995. The company accelerates pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. QPS regional laboratories and testing facilities are located at the headquarters in Newark, Delaware, as well as Springfield, Missouri; Fargo, North Dakota; Miami, Florida; Groningen, the Netherlands; Graz, Austria; Hyderabad, India; Suzhou, China; and Taipei, Taiwan. For more information, visit www.qps.com or email [email protected].
G-CURE originated at the Department of Cardiology at the UMCG in Groningen, the Netherlands, and has a long-standing history of high-quality scientific output of international cardiovascular research. G-CURE’s primary focus area is the preservation of cardiac function, with special interest in heart failure, atrial fibrillation, and ischemic heart disease.
Together with their clients, the team members at G-CURE design and set up research development plans for cardiovascular compounds or devices – from preclinical trials to proof-of-concept clinical studies. G-CURE offers clients the unique opportunity to exploit its vast network of experienced and well-established partners in every aspect of drug development (including the regulatory process, consultancy services, preclinical and clinical study execution, data management, and expert report writing).
All major partners of G-CURE are located on the premises of the UMCG. For more information, visit https://www.gcure.nl. The following are the collaborating cardiologists and their fields of expertise:
- Prof. Dr. A.A. Voors (heart failure)
- Prof. Dr. R.A. de Boer (heart failure, experimental cardiology)
- Prof. Dr. P. van der Meer (heart failure, amyloidosis)
- Prof. Dr. P. van der Harst (myocardial ischemia, interventional cardiology)
- Prof. Dr. M.P. van den Berg (genetic cardiomyopathies e.g. PLN mutations)
- Prof. Dr. I.C. van Gelder (electrophysiology, arrythmias)
- Prof. Dr. M. Rienstra (electrophysiology, arrhythmias)
- Prof. Dr. D.J. van Veldhuisen (heart failure)
QPS Holdings, LLC:
Edwin Van Vulpen, Head of Clinical Business Development Europe
+31 61 0000195
Ruben de Jong, COO G-CURE & Head Cardio Research
+31 50 3613875